Goals · Specialty & Clinical
Estrogen management, prolactin control, and side-effect mitigation during active cycles. AIs, DAs, and 19-nor support.
Compounds linked to this goal in the catalogue, ordered by role — primary, then support, then optional. Roles follow peptide-db's per-use effectiveness rating (most effective → primary, effective → support, moderate or thinner → optional); a compound that reaches the goal through a curated stack or a condition page says so. Click any card for the full mechanism, dosing, and evidence.
No peptides tagged for this goal yet.
No SARMs tagged for this goal yet.
Aromatase Inhibitor | Estrogen Management
Half-life: ~40-50 hours
Dopamine Agonist | Prolactin Management
Half-life: ~63-69 hours
Steroidal Aromatase Inhibitor | Irreversible Estrogen Control
Half-life: ~24 hours
Aromatase Inhibitor | Potent Estrogen Suppression
Half-life: ~2 days (48 hours)
Selective Estrogen Receptor Modulator | Gynecomastia & Bone Health
Half-life: ~28 hours
Selective Estrogen Receptor Modulator | PCT & Breast Cancer Treatment
Half-life: ~5-7 days
Dopamine Agonist | Prolactin Management Alternative
Half-life: ~8 hours
Support — Prolactin Management on Nandrolone · effective